US COVID-19 Vaccination Threatened By Out-of-print Drug

The Pfizer coronavirus drug has already been sold out, which is why the vaccination of the population in the United States is at risk, according to the "360" TV channel. The American company Pfizer reported the shortage of vaccine to the administration of US President Donald Trump. The drug was sold out by other countries, so additional doses in the United States may not appear until the end of June or July. In this regard, the question arises about the implementation of the schedule of vaccination of American citizens against coronavirus. The authorities planned to vaccinate most of the population by the end of spring or early summer. The U. S. government has signed an agreement with Pfizer and the German biotech company BioNTech to purchase up to 600 million doses of COVID-19 vaccine. According to the contract, after the delivery of the first 100 million doses, the companies will receive $ 1.95 billion. In addition, the authorities will be able to purchase up to 500 million doses. Pfizer spokesman Amy Rose did not confirm to the publication the information about the negotiations. She also said that in order to purchase additional doses of the drug, it will be necessary to sign another agreement. The newspaper notes that the Trump administration has denied possible problems with the availability of the drug, as there are other vaccines in development. At the same time, officials familiar with the contracts assured that the drugs from other companies would not be enough to fill the gaps.